Market Research Logo

Vaccine Contract Manufacturing Market, 2016 - 2026

Vaccine Contract Manufacturing Market, 2016 - 2026

Vaccines have always been viewed as a low-margin business characterized by high entry barriers. Developmental and production related complexities, combined with significant fixed costs and stringent regulatory standards, have limited competition among vaccine manufacturers. In addition, these complexities have also restricted innovation in this space to a great extent. However, recent advances in biotechnology and biomanufacturing have resulted in the development of advanced technologies capable of addressing the challenges associated with manufacturing vaccines. Previously, the vaccine market was solely focused on preventive vaccines developed against infectious diseases. The advent of therapeutic vaccines has renewed interest in this field by paving way for vaccines to be developed for a variety of chronic and degenerative diseases. This has led to the entry of a number of established and emerging stakeholders who are competing for a share in this growing market segment.

It is well-known that the overall trend of outsourcing has grown significantly in the biopharmaceuticals industry. Due to the complex nature of vaccine development and manufacturing processes, both large and small stakeholders are exploring outsourcing opportunities for their products. Operational and infrastructural cost-benefits and reduced time-to-market are the major factors driving outsourcing. Manufacturing vaccines requires specialized resources and highly regulated technology platforms, which are becoming increasingly difficult to establish in-house. Although big pharma players prefer to carry out most of these processes in-house, they are gradually entering into long-term partnerships with trusted contract manufacturing organizations (CMOs). On the other hand, smaller and emerging players have been known to outsource a relatively larger share of their clinical development and commercial manufacturing processes to contract manufacturing partners. The landscape is rapidly evolving. CMOs aiming to consolidate their presence in the market are expanding their service portfolios to provide end-to-end services to their clients and sponsors.

SCOPE OF THE REPORT
The Vaccine Contract Manufacturing Market, 2016 – 2026 report provides an extensive study of the current market landscape of CMOs focused on vaccines. The study presents an in-depth analysis of a diverse set of biopharmaceutical CMOs based on key parameters such as geographical location, scale of operation, use of expression systems and manufacturing capabilities. In addition, it captures some of the potential growth areas that will likely present tremendous opportunities for vaccine CMOs and contribute to an accelerated pace of growth.

The report assesses the key drivers that have governed the evolution of vaccine contract manufacturing market over the past several years, along with an elaborate discussion on the future trends that are likely to shape the market in the coming years. One of the focus areas of this study is to estimate size of the future opportunity for vaccine CMOs market over the next decade, segmented on the basis of business operations, type of expression systems and key regions.

The study also provides information on some of the most important aspects of vaccine outsourcing; these include growing collaborations, investment activity, facility expansions and technological advances. In addition to some of the well-known benefits and a promising outlook, the study highlights considerable challenges that are currently prevalent in the market. Examples include quality concerns, stringent regulations and lack of funding. Nevertheless, these challenges are resulting in new strategies and technological improvements, which are likely to prove advantageous in the long run.

The base year for the report is 2016; it provides market forecasts for the period 2016 - 2026. The research, analysis and insights presented in this report is backed by a deep understanding of key insights gathered both from secondary and primary research.

EXAMPLE HIGHLIGHTS
1. Vaccine development and manufacturing, characterized by complex production processes and high entry barriers, is set in a highly regulated market landscape. Outsourcing has emerged as a rising trend in this domain and gained a lot of traction in the last few years. As the market continues to evolve, CMOs are rapidly enhancing their service offering to offer end-to-end services to their clients.
2. Developed regions, such as North America and Europe, currently dominate the vaccine contract manufacturing market. Of the 79 CMOs we identified, 41 have presence in multiple locations in the US. In Europe, the other major hub for CMOs, 20 CMOs have facilities located in Germany, France and the UK alone.
3. CMOs in emerging locations have also gained ground. With increasing support from local governments, many low-income geographies have restructured their indigenous regulatory landscape. Intellectual property protection laws have been made more stringent in favor of foreign sponsors looking to outsource business operations in the same regions. Established players in this market have also received the necessary qualifications and certifications to provide services in compliance with global standards.
4. Out of 79 CMOs, 21 offer end-to-end services across preclinical, clinical and commercial scale. We observed a rapid adoption of mammalian and insect production technologies among service providers.
5. The highly competitive market landscape is abuzz with partnership activity. We have identified 128 unique partnerships that were inked in the recent past. Of these, a sizeable proportion (25%) is mergers / acquisitions. We believe this trend is likely to continue in the future.
6. Technological advances are amongst the major driving factors in this market. The introduction of novel expression systems, such as the EB66® and GPEx® cell lines, and cell culture media platforms have sustained the interest of players in this field. Single use / disposable technologies, a key bio-manufacturing trend, are also becoming more and more popular among contract manufacturers. This is representative of the current market intensity.
7. Driven by increasing global demand and the rapidly expanding vaccine market, we expect the overall contract manufacturing market in this space to grow at an annualized rate of 9.8%. The rate of growth is likely to vary significantly across different segments / activities and across geographical regions.

RESEARCH METHODOLOGY
Most of the data presented in this report has been gathered via secondary and primary research. For all our projects, we conduct interviews with experts in the area (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will evolve across different regions and technology segments. Where possible, the available data has been checked for accuracy from multiple sources of information.

The secondary sources of information include
 Annual reports
 Investor presentations
 SEC filings
 Industry databases
 News releases from company websites
 Government policy documents
 Industry analysts’ views

While the focus has been on forecasting the market over the coming ten years, the report also provides our independent view on various non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.

CHAPTER OUTLINES
Chapter 2 provides an executive summary of the key insights captured in our research. The summary offers a high level view on the current status of the vaccine contract manufacturing market and where it is headed in the mid-long term.

Chapter 3 is a general introduction to vaccines. The chapter also includes an overview of the various expression systems used in the development of different vaccines and their related manufacturing procedures. It also provides an elaborate discussion on the need for outsourcing vaccine development and manufacturing processes. In this chapter, we have also presented a list of commonly outsourced biomanufacturing activities that we came across during the course of our research. The chapter also features a section dedicated to the challenges associated with the market.

Chapter 4 provides a comprehensive overview of the global landscape of vaccine CMOs. The chapter includes in-depth analysis based on regional distribution, scale of operation, manufacturing capabilities, type of vaccines manufactured and expression systems used.

Chapter 5 features an analysis of the trends, regulatory landscape and highlights the key players in vaccine contract manufacturing located in the US and Europe, the two leading geographies in this market. The chapter also provides a sub-market forecast for vaccine contract manufacturing segmented on the basis of expression systems used.

Chapter 6 provides details of vaccine contract manufacturing activities in China and India. It includes information on the regulatory framework, growth drivers and challenges associated with vaccine contract manufacturing in these regions. It also provides a high-level view on the production capabilities of some the key players in these emerging geographies. Additionally, a sub-market forecast for vaccine contract manufacturing segmented on the basis of expression systems used is also included in this chapter.

Chapter 7 presents an analysis of the recent developments in the vaccine contract manufacturing market. It provides a listing of the partnerships established in the recent past, along with an overview of other observed market trends, including investments and facility expansions.

Chapter 8 presents a detailed market forecast for the vaccine contract manufacturing market. Additionally, we have analyzed the future potential for specific geographies across the globe and in terms of the type of expression systems used. To account for the uncertain nature of the market, we have presented three different tracks of market evolution, namely the conservative, base and optimistic scenarios.

Chapter 9 provides a SWOT analysis capturing the key elements that are likely to influence the market’s future.

Chapter 10 highlights future trends that are likely to emerge in the evolving vaccine contract manufacturing market. It includes brief discussions on important aspects such as the adoption of innovative technologies and a shift to strategic partnering. The chapter also addresses the growing market demand and how it is likely to influence the future growth and evolution of this market.

Chapter 11 is a summary of the entire report. It provides the key takeaways and presents our independent opinion of the vaccine CMOs market, based on the research and analysis described in the previous chapters.

Chapter 12 contains the transcripts of interviews conducted with representatives from renowned organizations engaged in this space.

Chapter 13 is an appendix that contains tabulated data and numbers for all the figures provided in the report.

Chapter 14 is an appendix that provides the list of companies and organizations mentioned in the report.

LIST OF COMPANIES AND ORGANIZATIONS

LIST OF COMPANIES
1. 3P Biopharmaceuticals
2. ABL
3. Acambis
4. Accugenix
5. Actavis
6. Advanced BioScience Laboratories
7. Advaxis
8. Aeras
9. AJ Biologics
10. Albany Molecular Research (AMRI)
11. Alexion
12. Algonomics
13. Altaris Capital Partner
14. AmbioPharm
15. AnaSpec
16. Aptuit
17. Avid Bioservices
18. Bachem
19. Batavia Biosciences
20. Bavarian Nordic
21. Baxter BioPharma Solutions
22. BD Biosciences
23. Benchmark Vaccines
24. Bharat Biotech
25. BioCell Corporation
26. Biocon
27. BioConnections
28. BioConvergence
29. Biofabri
30. Bioline Group of Companies
31. Biological E
32. BioMARC
33. Biomay
34. BioMotiv
35. BioReliance Holdings
36. BioTechnique
37. Biovest International
38. Boehringer Ingelheim
39. Boehringer Ingelheim BioXcellence™
40. Bristol-Myers Squibb
41. Bryllan
42. CALIXAR
43. Catalent
44. Catalent Pharma Solutions
45. Celsis International
46. CEPiA Sanofi (Transgene)
47. Cetus Corporation
48. CEVEC Pharmaceuticals
49. Charles River Laboratories International
50. Chimera Biotec
51. China National Biotec Group
52. Cobra Biologics
53. Cook Pharmica
54. Crucell Sweden
55. Cytovance Biologics
56. Daiichi Sankyo
57. Deltamune
58. Dr. Reddy's Laboratories
59. Emergent BioSolutions
60. Eubiologics
61. Eurogentec
62. Florida Biologix
63. FUJIFILM Diosynth Biotechnologies
64. Gallant Custom Laboratories
65. Gamma Vaccines
66. Genentech
67. GENEWIZ
68. GlaxoSmithKline
69. GNH India
70. Goodwin Biotechnology
71. Grand River Aseptic Manufacturing
72. GreenPak Biotech
73. HALIX
74. HLL Biotech
75. Hong Kong Institute of Biotechnology
76. IDT Biologika
77. Immune Design
78. Immune Targeting Systems
79. ImmunoSite Technologies
80. ImVisioN Therapeutics
81. Index Ventures
82. Indian Immunologicals
83. Integrity Bio
84. Intercell
85. International Medica Foundation
86. Interros Group
87. Inviragen
88. Irvine Pharmaceutical Services
89. Jubilant HollisterStier
90. KABS Pharmaceutical Services
91. Kaneka Corporation
92. KBI Biopharma
93. LigoCyte Pharmaceuticals
94. Lonza
95. Magellan Biosciences
96. MassBiologics
97. Medicago
98. Mefar Ilac (Birgi Mefar Group)
99. Meridian Life Science
100. Mitsubishi Gas Chemical Company
101. Mitsubishi Tanabe Pharma Corporation
102. Moderna Therapeutics
103. Mymetics Corporation
104. Novartis
105. Novasep
106. Novavax
107. NPO Petrovax Pharm
108. NTC
109. OctoPlus
110. Okairos
111. Oncotest
112. OSO Biopharmaceuticals Manufacturing (OsoBio)
113. Pacific GMP
114. Panacea Biotec
115. Paragon Bioservices
116. PATH
117. Pfenex
118. Pfizer
119. Pfizer CentreOne
120. Pharmapak
121. PharmaSynth
122. Premas Biotech
123. Prime European Therapeuticals
124. ProBioGen
125. Protagen
126. PX’Therapeutics
127. QuiaPEG
128. RAFAGEN
129. Recipharm
130. Richter-Helm
131. Riemser Pharma
132. SAFC
133. Sanofi
134. Sanofi Pasteur
135. Sartorius Stedim Biotech
136. Serum Institute
137. Shandong Zhaoxin Bio-tech Company
138. ShangPharma
139. Sigma-Aldrich
140. Statens Serum Institut
141. Stellar Biotechnologies
142. SynCo Bio Partners
143. Temasek Life Sciences Ventures
144. Thermo Fisher Scientific
145. Tianjin CanSino Biotechnology
146. Unitech Pharma Group
147. Univercells
148. Upperton
149. Vaccibody
150. Vacsera
151. Valneva
152. Vetter Pharma International
153. VGXI
154. Vibalogics
155. Vivalis
156. Vybion (Recombinant Protein Technologies and Products)
157. Waisman Biomanufacturing
158. WIL Research
159. WuXi AppTec
160. Zoetis

LIST OF ORGANIZATIONS
1. Air Force Hospital, Guangzhou
2. Association for Assessment and Accreditation of Laboratory Animal Care
3. Association Sportive du Golf Club Val de l'Indre
4. Australian Therapeutic Goods Administration
5. Bill and Melinda Gates Foundation
6. Biomedical Advanced Research and Development Authority
7. Biopharmaceutical Development Program - Frederick National Laboratory for Cancer Research
8. Biotechnology and Biological Sciences Research Council
9. Biotechnology and Biological Sciences Research Council
10. Canadian Animal Health Institute
11. Canadian Council on Animal Care
12. Centers for Disease Control and Prevention
13. China Agricultural University
14. Chinese Center for Disease Control and Prevention
15. Council of the Chinese University of Hong Kong
16. Developing Countries Vaccine Manufacturers Network
17. Engineering and Physical Sciences Research Council
18. European Medicines Agency
19. Federation of Indian Chambers of Commerce and Industry
20. Friedrich-Loeffler-Institut
21. Global Alliance for Vaccines and Immunizations
22. Government of India's Universal Immunisation Programme
23. Guangxi Veterinary Research Institute
24. Haffkine Institute
25. Harbin Veterinary Research Institute
26. Harbin Veterinary Research Institute, China
27. HK Jockey Club Charities Trust
28. Indian Council of Medical Research
29. Infectious Disease Research Institute
30. Innovation & Technology Commission, HKSAR Government, China
31. International Society for Pharmaceutical Engineering
32. Ministry of Health & Family Welfare, Government of India
33. National Avian Influenza Reference Laboratory
34. National Heart, Lung and Blood Institute
35. National Institutes of Allergy and Infectious Diseases
36. Norwegian Institute of Public Health
37. Organization for Economic Cooperation and Development
38. Shanghai Laboratory Animal Commission
39. South China Agricultural University
40. Swiss State Secretariat Education, Research and Innovation
41. Technology Strategy Board
42. The College of Animal Science and Technology, Sichuan Agricultural University, China
43. UK Medicines Control Agency
44. United States Food and Drug Association
45. University of Maryland
46. University of Oxford
47. University of Pennsylvania
48. Walter Reed Army Institute of Research - Pilot Bioproduction Facility
49. Wellcome Trust
50. World Trade Organization


1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Chapter Overview
3.2. Classification of Vaccines: Based on Type Active Ingredient
3.2.1. Live, Attenuated Vaccines
3.2.2. Inactivated Vaccines
3.2.3. Subunit Vaccines
3.2.4. Toxoid Vaccines
3.2.5. DNA Vaccines
3.3. Vaccine Formulations: Key Components
3.3.1. Adjuvants
3.4. Vaccine Development and Manufacturing
3.4.1. Identification of the Antigen and Manufacturing Process Development
3.4.2. Manufacturing Process
3.4.2.1. Upstream Process
3.4.2.1.1. Bacterial Expression Systems
3.4.2.1.2. Yeast Expression Systems
3.4.2.1.3. Insect Expression System
3.4.2.1.4. Embryonated Chicken Eggs and Primary Chicken Embryonic Fibroblasts (CEFs)
3.4.2.1.5. Mammalian Expression Systems
3.4.2.1.6. Plant Expression Systems
3.4.2.1.7. Avian Expression Systems
3.4.2.2. Downstream Process
3.4.2.3. Formulation and Fill/Finish
3.4.3. Clinical Development and Approval
3.5. Contract Manufacturing: Definition
3.5.1. Vaccine Contract Manufacturing: Addressing an Unmet Need
3.5.2. Vaccine Contract Manufacturing: Commonly Outsourced Operations
3.5.3. Vaccine Contract Manufacturing: Selecting a CMO Partner
3.5.4. Vaccine Contract Manufacturing: Risk Factors and Challenges
4. COMPETITIVE LANDSCAPE
4.1. Chapter Overview
4.2. Analysis by Region
4.3. Analysis by Scale of Operation
4.4. Analysis by Expression Systems
4.5. Analysis by Manufacturing Capabilities
5. VACCINE CONTRACT MANUFACTURING: DEVELOPED REGIONS
5.1. Chapter Overview
5.2. One Stop Shops: A Growing Trend in Vaccine Contract Manufacturing
5.3. Vaccine Outsourcing in the US
5.4. Vaccine Contract Manufacturing Market in the US, 2016 - 2026
5.5. Vaccine Contract Manufacturing Market in the US, 2016 – 2026: Distribution by Type of Expression Systems Used
5.6. Leading Vaccine CMOs in the US
5.6.1. Albany Molecular Research (AMRI) / OSO Biopharmaceuticals Manufacturing (OsoBio)
5.6.1.1. Company Overview
5.6.1.2. Vaccine-related Service Portfolio
5.6.1.2.1. Regulatory Support and Quality Assurance
5.6.1.2.2. Vaccine Manufacturing Infrastructure
5.6.1.3. Financial Performance
5.6.1.4. Recent Developments
5.6.1.4.1. Partnerships
5.6.1.4.2. Awards and Recognition
5.6.1.4.3. Expansions
5.6.2. Catalent
5.6.2.1. Company Overview
5.6.2.2. Vaccine-related Service Portfolio
5.6.2.2.1. Cell Line Development
5.6.2.2.2. Clinical Manufacturing
5.6.2.2.3. Analytical, Clinical Supply Services
5.6.2.2.4. Regulatory Services
5.6.2.2.5. Vaccine Manufacturing Facilities
5.6.2.2.5.1. Swindon, United Kingdom
5.6.2.2.5.2. Neder-Over-Heembeek, Belgium
5.6.2.2.5.3. Kansas City, Missouri
5.6.2.3. Financial Performance
5.6.2.4. Recent Developments
5.6.2.4.1. Partnerships
5.6.2.4.2. Funding Instances and Expansions
5.6.3. Charles River Laboratories
5.6.3.1. Company Overview
5.6.3.2. Vaccine-related Service Portfolio
5.6.3.2.1. Vaccine Development Services
5.6.3.2.2. Vaccine Manufacturing Services
5.6.3.2.3. Avian Vaccine Services
5.6.3.3. Financial Performance
5.6.3.4. Recent Developments
5.6.3.4.1. Partnerships
5.6.3.4.2. Awards and Recognition
5.6.3.4.3. Expansions
5.6.4. Lonza
5.6.4.1. Company Overview
5.6.4.2. Vaccine-related Service Portfolio
5.6.4.2.1. Process Development and Optimization
5.6.4.2.2. Commercial Manufacturing
5.6.4.2.3. Aseptic Fill/Finish
5.6.4.2.4. Other Services
5.6.4.3. Financial Performance
5.6.4.4. Recent Developments
5.6.4.4.1. Partnerships
5.6.4.4.2. Expansions
5.6.5. Meridian Life Science (MLS)
5.6.5.1. Company Overview
5.6.5.2. Vaccine-related Service Portfolio
5.6.5.2.1. Vaccine Manufacturing Facility at Memphis, Tennessee
5.6.5.2.1.1. Cell and Virus Banking
5.6.5.2.1.2. Process development and Scale-up Services
5.6.5.2.1.3. Formulation Development and Fill/finish
5.6.5.2.1.4. Regulatory Support
5.6.5.2.1.5. Other Services and Facilities
5.6.5.3. Financial Performance
5.6.5.4. Recent Developments
5.6.5.4.1. Partnerships
5.6.5.4.2. Awards and Recognition
5.6.5.4.3. Expansions
5.6.6. SAFC (A Unit of Sigma-Aldrich Corporation)
5.6.6.1. Company Overview
5.6.6.2. Vaccine-related Manufacturing Services
5.6.6.2.1. cGMP Cell and Virus Banking
5.6.6.2.2. Process Development
5.6.6.2.3. Biorepository Services
5.6.6.2.4. Contract Manufacturing Support Services
5.6.6.2.5. Vaccine Manufacturing Capabilities
5.6.6.2.5.1. Carlsbad Facility
5.6.6.3. Financial Performance
5.6.6.4. Recent Developments
5.6.6.4.1. Partnerships
5.6.6.4.2. Awards and Recognition
5.6.6.4.3. Expansions
5.7. Vaccine Outsourcing in Europe
5.8. Vaccine Contract Manufacturing Market in Europe, 2016 - 2026
5.9. Vaccine Contract Manufacturing Market in Europe, 2016 – 2026: Distribution by Type of Expression Systems Used
5.10. Leading Vaccine CMOs in Europe
5.10.1. Cobra Biologics
5.10.1.1. Company Overview
5.10.1.2. Vaccine-related Service Portfolio
5.10.1.2.1. DNA Vaccines and DNA based Services
5.10.1.2.2. Viral Vaccines and Virus based Services
5.10.1.2.3. Other Services
5.10.1.3. Recent Developments
5.10.1.3.1. Partnerships
5.10.1.3.2. Funding Instances and Expansions
5.10.2. Eurogentec
5.10.2.1. Company Overview
5.10.2.2. Vaccine-related Service Portfolio
5.10.2.2.1. Manufacturing Services
5.10.2.2.2. Analytical and Regulatory Support
5.10.2.2.3. Other Services
5.10.2.3. Recent Developments
5.10.2.3.1. Partnerships
5.10.3. IDT Biologika
5.10.3.1. Company Overview
5.10.3.2. Vaccine-related Service Portfolio
5.10.3.2.1. Development Services
5.10.3.2.2. Manufacturing Services
5.10.3.2.3. Fill/Finish Operations
5.10.3.2.4. Supporting Services
5.10.3.2.4.1. Labeling and Packaging
5.10.3.2.4.2. Storage
5.10.3.2.4.3. Quality Control
5.10.3.2.5. Vaccine Manufacturing Facilities
5.10.3.2.5.1. Riems, Germany
5.10.3.2.5.2. Dessau, Germany
5.10.3.2.5.3. Rockville, Maryland
5.10.3.3. Financial Performance
5.10.3.4. Recent Developments
5.10.3.4.1. Partnerships
5.10.3.4.2. Awards and Recognition
5.10.3.4.3. Expansions
5.10.4. SynCo Bio Partners
5.10.4.1. Company Overview
5.10.4.2. Vaccine-related Service Portfolio
5.10.4.2.1. Process Development
5.10.4.2.1.1. Microbial Process Development
5.10.4.2.1.2. Product Development for Live Biotherapeutics
5.10.4.2.2. Analytical and Quality Control Services
5.10.4.2.3. GMP Manufacturing
5.10.4.2.4. Aseptic Filling and Lyophilization Services
5.10.4.2.5. Quality Assurance and Regulatory Support
5.10.4.3. Recent Developments
5.10.4.3.1. Partnerships
5.10.4.3.2. Awards and Recognition
5.10.4.3.3. Expansions
6. VACCINE CONTRACT MANUFACTURING: EMERGING REGIONS
6.1. Chapter Overview
6.2. Vaccine Contract Manufacturing in China
6.2.1. Contract Manufacturing in China: Regulatory Landscape
6.2.2. Contract Manufacturing in China: Key Challenges
6.2.3. Vaccine Contract Manufacturing in China: Investments and Business Expansions
6.3. Vaccine Contract Manufacturing Market in China, 2016 - 2026
6.4. Vaccine Contract Manufacturing Market in China, 2016 – 2026: Distribution by Type of Expression Systems Used
6.5. Leading Vaccine CMOs in China
6.5.1. GreenPak Biotech
6.5.1.1. Company Overview
6.5.1.2. Vaccine-related Service Portfolio
6.5.2. Hong Kong Institute of Biotechnology
6.5.2.1. Company Overview
6.5.2.2. Vaccine-related Service Portfolio
6.5.2.2.1. The Biologics Unit at the Hong Kong Institute of Biotechnology
6.5.2.2.2. Vaccine Contract Manufacturing
6.5.3. WuXi AppTec
6.5.3.1. Company Overview
6.5.3.2. Vaccine-related Service Portfolio
6.5.3.2.1. Discovery and Early Diagnostic Testing Services
6.5.3.2.2. Non-Clinical Services
6.5.3.2.3. Support Services
6.5.3.2.4. Manufacturing Services
6.5.3.2.5. Vaccine Testing
6.5.3.3. Financial Performance
6.5.3.4. Recent Developments
6.5.3.4.1. Collaborations and Mergers
6.6. Vaccine Contract Manufacturing in India
6.6.1. Contract Manufacturing in India: Regulatory Landscape
6.6.2. Contract Manufacturing in India: Key Challenges
6.7. Vaccine Contract Manufacturing Market in India, 2016 - 2026
6.8. Vaccine Contract Manufacturing Market in India, 2016 – 2026: Distribution by Type of Expression Systems Used
6.9. Leading Vaccine CMOs in India
6.9.1. Bharat Biotech
6.9.1.1. Company Overview
6.9.1.2. Vaccine-related Service Portfolio
6.9.1.3. Financial Performance
6.9.1.4. Recent Developments
6.9.1.4.1. Partnerships
6.9.1.4.2. Awards and Fundings
6.9.2. Biological E
6.9.2.1. Company Overview
6.9.2.2. Vaccine-related Service Portfolio
6.9.2.2.1. Complete Service Portfolio
6.9.2.3. Financial Performance
6.9.2.4. Recent Developments
6.9.2.4.1. Partnerships
6.9.2.4.2. Awards and Recognition
6.9.2.4.3. Expansions
7. RECENT DEVELOPMENTS
7.1. Chapter Overview
7.2. Vaccine Contract Manufacturing Market: Partnerships
7.2.1. Vaccine Contract Manufacturing Market: Growing Trend of Partnerships
7.2.2. Vaccine Contract Manufacturing Market: Analysis by Type of Partnership
7.2.3. Vaccine Contract Manufacturing Market: Analysis by Relevance of Partnership
7.3. Vaccine Contract Manufacturing Market: Capability Expansions
8. MARKET FORECAST
8.1. Chapter Overview
8.2. Forecast Methodology
8.3. Vaccine Contract Manufacturing Market. 2016 - 2026
8.4. Vaccine Contract Manufacturing Market: Regional Distribution
8.5. Vaccine Contract Manufacturing Market: Distribution by Type of Expression Systems Used
9. SWOT ANALYSIS
9.1. Chapter Overview
9.2. Strengths
9.3. Weaknesses
9.4. Opportunities
9.5. Threats
10. FUTURE TRENDS
10.1. Chapter Overview
10.2. Innovative Technologies to Drive Growth
10.3. The Advent of VLPs
10.4. Cell Culture Media Optimization
10.5. Growing Demand likely to Spur Additional Investments
10.6. Shift toward Strategic Partnering
10.7. Acquisition of Smaller Businesses
11. CONCLUSION
12. INTERVIEW TRANSCRIPTS
13. APPENDIX I TABULATED DATA
14. APPENDIX II LIST OF COMPANIES AND ORGANIZATIONS
LIST OF FIGURES
Figure 3.1 Vaccine Manufacturing: Common Processes
Figure 3.2 Types of Third Party Service Providers in the Pharmaceutical Industry
Figure 3.3 Commonly Outsourced Vaccine Development Operations
Figure 4.1 Vaccine CMOs: Geographical Presence by Country
Figure 4.2 Vaccine CMOs: Geographical Presence by Region
Figure 4.3 Vaccine CMOs: Distribution by Scale of Operation
Figure 4.4 Vaccine CMOs: Distribution by Expression Systems
Figure 4.5 Vaccine CMOs: Availability of Manufacturing Capabilities
Figure 5.1 Vaccine Contract Manufacturing Market in the US: Growth Drivers and Challenges
Figure 5.2 Vaccine Contract Manufacturing Market in the US, 2016 – 2026: Base Scenario (USD Billion)
Figure 5.3 Vaccine Contract Manufacturing Market in the US, 2016 - 2026: Distribution by Type of Expression Systems Used (USD Billion)
Figure 5.4 AMRI (OsoBio): Vaccine-related Service Portfolio
Figure 5.5 AMRI (OsoBio): Annual Revenues, FY 2011 – Q1 2016 (USD Million)
Figure 5.6 AMRI (OsoBio): Revenues by Business Segments, FY 2015 (USD Million)
Figure 5.7 Catalent: Vaccine-related Service Portfolio
Figure 5.8 Catalent: Annual Revenues, FY 2011 – FY 2015 (USD Billion)
Figure 5.9 Catalent: Revenues by Business Segments, FY 2015 (USD Billion)
Figure 5.10 Charles River Laboratories: Products and Services
Figure 5.11 Charles River Laboratories: Annual Revenues, FY 2011 – FY 2015 (USD Billion)
Figure 5.12 Charles River Laboratories: Revenues by Business Segments, FY 2015 (USD Billion)
Figure 5.13 Lonza: Vaccine-related Service Portfolio
Figure 5.14 Lonza: Annual Revenues, FY 2011 – FY 2015 (CHF Billion)
Figure 5.15 Lonza: Revenues by Business Segments, 2015 (CHF Billion)
Figure 5.16 MLS: Process Development and Scale-up Services
Figure 5.17 MLS: Annual Revenues, FY 2011 – FY 2015 (USD Million)
Figure 5.18 MLS: Revenues by Business Segments, FY 2015 (USD Million)
Figure 5.19 SAFC: Contract Manufacturing Services and Solutions
Figure 5.20 SAFC: Contract Manufacturing Support Services
Figure 5.21 SAFC Carlsbad Facility: Vaccine Manufacturing Services
Figure 5.22 Sigma-Aldrich: Annual Revenues, FY 2010 – FY 2014 (USD Billion)
Figure 5.23 Sigma-Aldrich: Revenues by Business Segments, FY 2014 (USD Billion)
Figure 5.24 Vaccine Contract Manufacturing in Europe: Growth Drivers and Challenges
Figure 5.25 Vaccine Contract Manufacturing Market in Europe, 2016 – 2026: Base Scenario (USD Billion)
Figure 5.26 Vaccine Contract Manufacturing Market in Europe, 2016 - 2026: Distribution by Type of Expression Systems Used (USD Billion)
Figure 5.27 Eurogentec: Manufacturing Technologies and Capabilities
Figure 5.28 IDT Biologika: Vaccine-related Service Portfolio
Figure 5.29 IDT Biologika: Annual Revenues, FY 2011 – FY 2015 (EUR Million)
Figure 5.30 SynCo Bio Partners: Vaccine-related Service Portfolio
Figure 6.1 Contract Manufacturing Market in China: Key Growth Drivers
Figure 6.2 Vaccine Contract Manufacturing Market in China, 2016 – 2026: Base Scenario (USD Billion)
Figure 6.3 Vaccine Contract Manufacturing Market in China, 2016 – 2026: Distribution by Type of Expression Systems Used (USD Billion)
Figure 6.4 Hong Kong Institute of Biotechnology: Service Portfolio
Figure 6.5 WuXi AppTec: Vaccine Development Services
Figure 6.6 WuXi AppTec: Vaccine Testing Services
Figure 6.7 Contract Manufacturing Market in India: Key Drivers and Concerns
Figure 6.8 Vaccine Contract Manufacturing Market in India, 2016 – 2026: Base Scenario (USD Billion)
Figure 6.9 Vaccine Contract Manufacturing Market in India, 2016 - 2026: Distribution by Type of Expression Systems Used (USD Billion)
Figure 6.10 Biological E: Vaccine-related Service Portfolio
Figure 7.1 Vaccine Contract Manufacturing Market: Cumulative Trend of Partnerships, Pre 2009 - 2016
Figure 7.2 Vaccine Contract Manufacturing Market: Distribution by Type of Partnership
Figure 7.3 Vaccine Contract Manufacturing Market: Distribution by Relevance of Partnership
Figure 8.1 Share of Contract Manufacturers in the Vaccines Market
Figure 8.2 Vaccine Market, 2016 – 2026 (USD Billion)
Figure 8.3 Vaccine Manufacturing Market, 2016 – 2026: Base Scenario (USD Billion)
Figure 8.4 Vaccine Contract Manufacturing Market, 2016 - 2026: Regional Distribution (USD Billion)
Figure 8.5 Vaccine Contract Manufacturing Market: Regional Distribution 2016, 2021 and 2026
Figure 8.6 Vaccine Contract Manufacturing Market, 2016 - 2026: Distribution by Type of Expression Systems Used (USD Billion)
Figure 9.1 Vaccines in the Development Pipeline: By Therapeutic Area
LIST OF TABLES
Table 3.1 Vaccines and Small Molecule Drugs: Key Differences
Table 3.2 Vaccines: Classification Based on Method of Development
Table 3.3 Live Attenuated Vaccines: Commonly Reported Adverse Events
Table 3.4 Inactivated Vaccines: Commonly Reported Adverse Events
Table 3.5 Subunit Vaccines: Commonly Reported Adverse Events
Table 3.6 Toxoid Vaccines: Commonly Reported Adverse Events
Table 3.7 Vaccine Excipients and their Functions
Table 4.1 Vaccine CMOs: Geographical Distribution
Table 4.2 Vaccine CMOs: Overview of Scales of Operation
Table 4.3 Vaccine CMOs: Types of Expression Systems Used
Table 4.4 Vaccine CMOs: Manufacturing Capabilities
Table 5.1 Companies Providing One Stop Shop Services
Table 5.2 AMRI (OsoBio): Partnerships
Table 5.3 Catalent: Biologics Manufacturing and Laboratory Facilities
Table 5.4 Catalent: Partnerships
Table 5.5 Charles River Laboratories: Partnerships
Table 5.6 Lonza: Partnerships
Table 5.7 MLS: Partnerships
Table 5.8 SAFC: Partnerships
Table 5.9 Cobra Biologics: Production Facilities
Table 5.10 Cobra Biologics: Partnerships
Table 5.11 Cobra Biologics: Funding Instances
Table 5.12 Eurogentec: Partnerships
Table 5.13 IDT Biologika: Partnerships
Table 5.14 SynCo Bio Partners: Partnerships
Table 6.1 Hong Kong Institute of Biotechnology: Vaccine Contract Manufacturing Services
Table 6.2 WuXi AppTec: Biologics Development and Manufacturing Services
Table 6.3 Bharat Biotech: Partnerships
Table 6.4 Biological E: Partnerships
Table 7.1 Vaccine Contract Manufacturing Market: Partnerships
Table 9.1 Vaccine Contract Manufacturing Market: SWOT Analysis
Table 13.1 Vaccine CMOs: Geographical Presence by Country
Table 13.2 Vaccine CMOs: Geographical Presence by Region
Table 13.3 Vaccine CMOs: Distribution by Scale of Operation
Table 13.4 Vaccine CMOs: Distribution by Expression Systems
Table 13.5 Vaccine CMOs: Availability of Manufacturing Capabilities
Table 13.6 Vaccines Contract Manufacturing Market in the US, 2016 – 2026: Base Scenario (USD Billion)
Table 13.7 Vaccine Contract Manufacturing Market in the US, 2016 - 2026: Distribution by Type of Expression Systems Used (USD Billion)
Table 13.8 AMRI (OsoBio): Annual Revenues, FY 2011 – Q1 2016 (USD Million)
Table 13.9 AMRI (OsoBio): Revenues by Business Segments, FY 2015 (USD Million)
Table 13.10 Catalent: Annual Revenues, FY 2011 – FY 2015 (USD Billion)
Table 13.11 Catalent: Revenues by Business Segments, FY 2015 (USD Billion)
Table 13.12 Charles River Laboratories: Annual Revenues, FY 2011 – FY 2015 (USD Billion)
Table 13.13 Charles River Laboratories: Revenues by Business Segments, FY 2015 (USD Billion)
Table 13.14 Lonza: Annual Revenues, FY 2011 – FY 2015 (CHF Billion)
Table 13.15 Lonza: Revenues by Business Segments, 2015 (CHF Billion)
Table 13.16 MLS: Annual Revenues, FY 2011 – FY 2015 (USD Million)
Table 13.17 MLS: Revenues by Business Segments, FY 2015 (USD Million)
Table 13.18 Sigma-Aldrich: Annual Revenues, FY 2010 – FY 2014 (USD Billion)
Table 13.19 Sigma-Aldrich: Revenues by Business Segments, FY 2014 (USD Billion)
Table 13.20 Vaccines Contract Manufacturing Market in Europe, 2016 – 2026: Base Scenario (USD Billion)
Table 13.21 Vaccine Contract Manufacturing Market in Europe, 2016 - 2026: Distribution by Type of Expression Systems Used (USD Billion)
Table 13.22 IDT Biologika: Annual Revenues, FY 2011 – FY 2015 (EUR Million)
Table 13.23 Vaccines Contract Manufacturing Market in China, 2016 – 2026: Base Scenario (USD Billion)
Table 13.24 Vaccine Contract Manufacturing Market in China, 2016 – 2026: Distribution by Type of Expression Systems Used (USD Billion)
Table 13.25 Vaccines Contract Manufacturing Market in India, 2016 – 2026: Base Scenario (USD Billion)
Table 13.26 Vaccine Contract Manufacturing Market in India, 2016 - 2026: Distribution by Type of Expression Systems Used (USD Billion)
Table 13.27 Vaccine Contract Manufacturing Partnerships: Cumulative Trend, Pre 2009 - 2016
Table 13.28 Vaccine Contract Manufacturing Partnerships: Distribution by Type of Partnership
Table 13.29 Vaccine Contract Manufacturing Partnerships: Distribution by Relevance of Partnership
Table 13.30 Vaccine Market, 2016 – 2026 (USD Billion)
Table 13.31 Vaccine Manufacturing Market, 2016 – 2026: Base Scenario (USD Billion)
Table 13.32 Vaccine Contract Manufacturing Market, 2016 - 2026: Regional Distribution (USD Billion)
Table 13.33 Vaccine Contract Manufacturing Market, 2016 - 2026: Regional Distribution 2016, 2021 and 2026
Table 13.34 Vaccine Contract Manufacturing Market, 2016 - 2026: Distribution by Type of Expression Systems Used (USD Billion)

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report